Research Article

IMP3 Immunohistochemical Expression in Inverted Papilloma and Inverted Papilloma-Associated Sinonasal Squamous Cell Carcinoma

Sarah A. Hakim, Nermine M. Abd Raboh, and Lobna S. Shash

Department of Pathology, Faculty of Medicine, Ain Shams University, Egypt

Correspondence should be addressed to Sarah A. Hakim; sarahadel2003@yahoo.com

Received 6 November 2020; Accepted 8 February 2021; Published 17 February 2021

Academic Editor: Constantin Caruntu

Copyright © 2021 Sarah A. Hakim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sinonasal inverted papilloma (IP) is a common nonmalignant lesion in the nasal cavity and paranasal sinuses. Although benign, it has a high recurrence rate (up to 78% of cases), destroys surrounding structures (including bone erosion and orbital wall involvement), and may undergo malignant transformation (in 5–15% of cases). In fact, sinonasal IPs are concomitantly diagnosed in 1.7–56% of patients with sinonasal squamous cell carcinoma (SCC). Moreover, malignant transformation in such lesions has worse long-term clinical outcomes that include metastasis, postoperative disfigurement, and/or death [1–3]. Thus, precise and early diagnosis, thorough follow-ups, and discovering new prognostic and therapeutic indicators have become necessary in the management of sinonasal IP.

The oncofetal RNA-binding protein insulin-like growth factor 2 mRNA binding protein 3 (IMP3) is expressed during the early stages of embryogenesis and plays a role in cell growth and migration. These functions are mediated by post-transcriptional regulation of cell proliferation via regulation of IGF-2 transcription. After birth, IMP3 becomes epigenetically silenced, such that normal adult tissues show no detectable expression of this protein. However, its reexpression was...
noted in a series of human malignancies but not in the adja-
cent normal epithelium [4–6]. Moreover, several studies have
demonstrated a prognostic role for IMP3 in several malig-
nancies and their progression [7–13].

Only a few studies have assessed the immunohistochem-
ical (IHC) expression of IMP3 in head and neck SCC [6, 14–
18], and none have been conducted on sinonasal tumors.
Thus, the primary objectives of the current study were to
evaluate the IHC expression of IMP3 in the normal sinonasal
epithelium, sinonasal IP, and IP-associated sinonasal SCC
and to analyze its expression in relation to Ki-67 being an
established biomarker. A secondary objective is comparing
the IHC expression of IMP3 to established clinicopathologi-
cal parameters of SCC on top of IP.

2. Materials and Methods

2.1. Tissue and Patient Data. The current study was a retro-
spective study conducted on three groups: 72 cases of sinona-
sal IP, 20 age-matched samples of normal respiratory
epithelium obtained from cases with inflammatory/allergic
nasal polypi and cases submitted to exclude fungal infection
that proved to be free of fungal infection by periodic acid
Schiff, and 15 cases of sinonasal SCC associated with IP. They
were obtained from the archives of the Pathology Lab of Ain
Shams University Specialized and Ain Shams University
Hospitals. These were received and diagnosed during the
period from January 2012 to December 2019. All cases
underwent surgical intervention such as transnasal endo-
scopic resection and open surgical resection. The archival
files were reviewed to determine the age and sex of patients.
Hematoxylin and Eosin (H&E) stained slides were examined
to reevaluate and verify the histopathologic diagnosis and
histologic grade according to the World Health Organization
(WHO) tumor differentiation [19–21]. TNM staging was
performed according to the American Joint Committee on
Cancer (AJCC) [22]. Normal sinonasal respiratory epithelial
samples were also confirmed by histology.

ENT reports of the patients of the third group of IP-
associated SCC were reviewed to determine (a) survival time,
which was calculated based on the date of major surgery and
the date of last follow-up or death, and (b) progression-free
survival time, which was calculated based on the date of
major surgery or last session of adjuvant postoperative radio-
therapy and the date of relapse (local recurrence/distant
metastasis) at the last follow-up.

2.1.1. Ethics Statement. Signed written and informed consent
was obtained from all participants prior to surgery. The study
was approved by the Research Ethical Committee at the Fac-
culty of Medicine, Ain Shams University.

2.1.2. Immunohistochemical Staining. Four-micrometer sec-
tions of formalin-fixed and paraffin-embedded samples of
normal respiratory epithelium, sinonasal IP, and sinonasal
SCC associated with IP were prepared. IHC staining was per-
formed on samples of the three groups using rabbit monoclona-
lar anti-Ki-67 (Clone: SP6; Cell Marque, Sigma-Aldrich Co.,
California, USA; 1:200 dilution). Avidin-Biotin immunoperox-
dase complex technique was used by applying the sensi-
tive detection kit (BioGenex, Fremont, California, USA)
[23]. This was followed by fixation on poly-L-lysine-coated
slides overnight at 37°C. They were then deparaffinized
and rehydrated using graded alcohol series. Heating of the
sections in a microwave oven in 10 mM citrate buffer
(pH 6.0) was performed for 20 minutes. Blocking of endoge-
nous peroxidase, incubation in Protein Block Serum-Free
Solution (DakoCytomation, Glostrup, Denmark) for 20
minutes, then incubation overnight at 4°C with primary anti-
bodies were done. Addition of biotinylated anti-mouse
immunoglobulin and streptavidin conjugated to horseradish
peroxidase was then performed. Finally, 3,3′-diaminobenzi-
dine as the substrate or chromogen was used to form an
insoluble brown product. The sections were counterstained
with hematoxylin and mounted. Sections of pancreatic ductal
adenocarcinoma samples were used as positive control for
IMP3 while sections of tonsillar tissue were used as positive
control for Ki-67, with each run of every staining procedure
performed. Negative control sections of each lesion were
incubated with normal mouse serum instead of each of the
primary antibodies.

2.1.3. Interpretation of Immunohistochemical Staining. IHC
analysis of IMP3 and Ki-67 were blindly performed by three
pathologists (the authors). Cytoplasmic staining of IMP3 and
nuclear staining of Ki-67 in cells in any of the lesions of the
three groups were regarded as positive staining. Slides were
scanned by three pathologists at 20x magnification to identify
representative hot spots for counting positive cells. The
counting of cells with cytoplasmic positivity for IMP3 and
cells with nuclear positivity for Ki-67 was performed at
400x magnification. Next, the proportion of positive cells
over the total number of counted cells was independently
estimated by each of the three pathologists, and the average
was calculated. A multiheaded microscope was used to
resolve any discrepancies.

The assessment of the intensity of cytoplasmic staining of
IMP3 and the nuclear staining of Ki-67 was carried out by
subjective consideration of staining intensity, which was
scored as follows: 0: negative, 1: weak positivity, 2: moderate
positivity, and 3: strong positivity. Any discrepancies were
resolved by consensus using a multiheaded microscope [6].

All readings were performed independently and without
any prior knowledge of the clinical or histopathological char-
acteristics of the cases.

2.2. Statistical Analysis. Data was tested for normality with a
Shapiro-Wilk test and expressed as mean ± standard
deviation for parametric numerical data or median (inter-
quartile range) for nonparametric numerical data. Categori-
cal variables were expressed as frequencies and percent.
Student’s t test or Mann-Whitney test was used to compare
quantitative data between two groups according to data dis-
tribution. ANOVA or Kruskal–Wallis tests with post hoc test
were used to compare quantitative data between two and
more than 2 group tests according to data distribution.
Spearman correlation analysis was used to test the strength of correlation between two variables. The ROC curve was used to evaluate the sensitivity and specificity of IMP3 and Ki-67 in predicting SCC. Multivariate logistic regression analysis was performed for determining the predictors of SCC. A significance level of $P < 0.05$ was used in all tests. All statistical procedures were carried out using SPSS version 20 for Windows (SPSS Inc., Chicago, IL, USA).

3. Results

3.1. Patients. Data describing age and gender of the three studied groups are demonstrated in Table 1.

Among the 15 cases in the sinonasal SCC group, 2 cases (13.3%) were grade 1, 10 cases (66.7%) were grade 2, and 2 cases (13.3%) were grade 3.

3.2. Immunohistochemical Analysis. The overall IMP3 IHC expression revealed a pattern of cytoplasmic expression of low intensity in a few cells of the normal epithelium and sinonasal IP groups. On the other hand, a higher percentage of tumor cells showed IMP3 expression of high intensity among the third group of IP-associated SCC. Ki-67 IHC expression in the normal epithelium and sinonasal IP was characterized by nuclear staining of low to moderate intensity in a few cells. In the sinonasal SCC group, a high percentage of Ki-67 nuclear positivity was detected in the tumor cells (Figures 1, 2, and 3).

IMP3 expression was characterized by heterogeneity among SCC cases, such that negative areas alternate with positive areas of low intensity cytoplasmic staining of tumor cells among well-differentiated SCC. This pattern of heterogeneity gradually increases among moderately differentiated cases, until a diffuse cytoplasmic staining of moderate to strong intensity is seen among poorly differentiated SCC (Figure 4).

The mean and median values of IMP3 and Ki-67 IHC expression are presented in Table 2, where both markers show statistically significant differences in expression values between the three groups ($P = 0.001$). Normal epithelium and IP groups had nearly similar values of IMP3 expression while there was a sharp increase in expression among SCC cases. Ki-67 showed a nearly similar pattern of expression as IMP3, with a sharp rise among the sinonasal SCC group (Table 2).

ROC analysis revealed that both IMP3 and Ki-67 could be used to discriminate sinonasal SCC cases from normal/IP cases, with IMP3 at a cut-off value of $≥9.5$ with 100% and 81.5% sensitivity and specificity, respectively, and Ki-67 at a cut-off value of $≥22.5$ with 100% and 62.5% sensitivity and specificity, respectively ($P < 0.0001$ for each) (Table 3). However, after adjustment of all factors using logistic regression, it was shown that the increase in IMP3 is the only statistically significant factor associated with SCC (OR = 2.4, CI = 1.3 – 4.5, $P < 0.01$) (Table 4).

| Table 1: Description of age and gender among the studied groups. |
|------------------|------------------|------------------|
|                  | Normal epithelium | Group Inverted papilloma | SCC |
|                  | Mean ±SD          | Mean ±SD          | Mean ±SD |
| Age              | 47.95 ±6.03       | 48.43 ±5.42       | 57.80 ±9.30 |
| Gender           |                  |                  |          |
| Male             | 9 45.0%           | 49 68.1%          | 13 86.7% |
| Female           | 11 55.0%          | 23 31.9%          | 2 13.3%  |

SD: standard deviation; SCC: squamous cell carcinoma.

3.3. Correlation between IMP3, Ki-67, and Clinicopathological Parameters. Both markers showed statistically significant correlation with each other within each of the three groups ($P = 0.0001$ for each) (Table 5).

Spearman’s rho analysis revealed that both IMP3 and Ki-67 expressions were significantly related to lymph node and tumor stages, but not significantly related to tumor grade (Table 6).

3.4. Survival Analysis. ROC analysis was used to select clinically important cut-off scores of progression and survival for IMP3 in the 15 cases of sinonasal SCC on top of IP. At each percentage score, the sensitivity and specificity for each survival outcome under study were plotted, thus generating a ROC curve. The score having the closest distance to the point with both maximum sensitivity and specificity was selected as the cut-off score leading to the greatest number of tumors which were correctly classified as having or not having the clinical outcome. Table 7 shows that IMP3 could be used to predict mortality, local recurrence, and distant metastasis in SCC on top of IP at cut-off levels $≥55$, $≥49$, and $≥49$, respectively, with 100% sensitivity and specificity.

Kaplan-Meier analysis showed the correlation between IMP3 and overall survival (OS), where OS was 100% at 70 months follow-up at a cut-off value $≤55$, whereas it was 0% at 28 months at IMP3 cut-off $>55$ ($P < 0.0001$). Local recurrence-free survival (LRFS) was 100% at 70 months follow-up at an IMP3 cut-off level $≤31$, whereas it was 0% at 20 months at a cut-off $>31$ ($P < 0.0001$). Metastasis-free survival (MFS) was 100% at 70 months follow-up at an IMP3 cut-off level $≤49$, whereas it was 0% at 32 months at a cut-off value $>49$ (Figure 5).

4. Discussion

Although a small number of sinonasal IP are associated with a synchronous or metachronous squamous cell carcinoma, malignant transformation of these lesions leads to long-term morbidity and/or mortality. This necessitates better and novel diagnostic, prognostic, and therapeutic approaches [24]. The oncofetal protein IMP3 has been shown to be expressed in human malignancies but not in nonmalignant lesions, which may serve as a diagnostic marker in such cases. These malignancies include cancers such as ovarian, serous endometrial, cervical adenocarcinomas, pleural, lung, colorectal, gastric, bladder, renal, and laryngeal SCC. On the
other hand, other studies have introduced IMP3 as a prognostic biomarker for certain malignant tumors such as those found in the bile duct, neuroendocrine tumors of the lung, and peritoneal mesothelioma [4–12]. However, only a few studies have assessed the role of IMP3 in head and neck tumors [6, 14–18], and none have assessed its expression in sinonasal tumors.

The current study showed that IMP3 and Ki-67 significantly correlated among the three studied groups. Moreover, both proteins had a specific pattern of expression that was nearly similar for the normal epithelium and IP groups and sharply increasing in the IP-associated SCC group. This was in agreement with the pattern described by Maržić et al. [6] for the same markers in laryngeal SCC. However, Humayun and Prasad showed a continuous gradual rise in expression for Ki-67 expression among control, precancerous lesions, and their oral SCC cases [25]. In another study, Altavilla et al. showed a wide range of Ki-67 IHC expressions.
among 19 cases of sinonasal IP. Increased and diffuse nuclear reactivity was observed among the three cases of IP showing dysplastic changes, one of which was harboring a focal carcinomatous change [26].

With its diverse morphology, IPs may be associated with varying degrees of atypia, dysplasia, carcinoma in situ, and SCC. By computed tomography scan, the sensitivity and specificity of the diagnosis of SCC in IP are low, and orbital wall invasion can be found in recurrent benign IP tumors [27]. Moreover, the histologic criteria of malignant transformation have not yet been well defined. Even the current WHO classification has not included “carcinoma ex sinonasal papilloma” among its topics, which might negatively affect the precise diagnosis of such a category [28]. It should also be noted that the IHC profile of this group is yet to be established, despite several IHC studies conducted in this context [27, 29–40].

Thus, the results of the current study are novel in this area, where ROC analysis revealed that both IMP3 and Ki-67 could be used to discriminate sinonasal SCC cases from IP cases. Furthermore, logistic regression demonstrated that IMP3 is the only statistically significant factor associated with sinonasal SCC after adjustment of other factors. This was in concordance with a previous study [6], whose results revealed that IMP3 was statistically significant in predicting whether the patient had laryngeal SCC or not.

Figure 3: Different cases of IP-associated sinonasal SCC: (a, c, e) IMP3 IHC cytoplasmic expression in tumor cells (IHC ×100); (b, d, f) Ki-67 IHC nuclear expression in tumor cells ((b, f) IHC ×100, (d) IHC ×200).
In the current study, IMP3 sensitivity and specificity in differentiating sinonasal SCC from noncancerous cases were 100% and 81.5%, respectively. This was unlike Maržič et al. and Chen et al. [6, 17], whose cases of laryngeal SCC did not show 100% sensitivity for IMP3 expression. Moreover, the present study showed heterogeneity in IMP3 expression among sinonasal SCC, such that negative areas were seen alternating with areas of low intensity in well-differentiated sinonasal SCC, focal strong cytoplasmic staining alternate with foci of cytoplasmic staining of low intensity (IHC ×100); (c) poorly differentiated SCC showed diffuse moderate to strong cytoplasmic staining (IHC ×100).

Table 2: Comparison between the studied groups with regard to IHC expression of IMP3 and Ki-67 values.

<table>
<thead>
<tr>
<th>Group</th>
<th>Normal epithelium</th>
<th>Inverted papilloma</th>
<th>SCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean ±SD</td>
<td>Median (IQR)</td>
<td>Mean ±SD</td>
<td>Median (IQR)</td>
</tr>
<tr>
<td>IMP3</td>
<td>6.86 ± 2.63</td>
<td>6.9 (5.1–8)</td>
<td>6.41 ± 3.1</td>
</tr>
<tr>
<td>Ki-67</td>
<td>21.76 ± 7.86</td>
<td>21 (16.5–28.9)</td>
<td>20.05 ± 6.43</td>
</tr>
</tbody>
</table>

*Kruskal-Wallis test. ^SCC vs. normal (HS: highly significant), SCC vs. inverted (HS), normal vs. inverted (NS: nonsignificant). ^S: SCC vs. normal (HS), SCC vs. inverted (S: significant), normal vs. inverted (NS).

Table 3: ROC curve using IMP3 and Ki-67 to differentiate SCC cases from noncancerous cases.

<table>
<thead>
<tr>
<th>IHC marker</th>
<th>AUC (CI)</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>+PV</th>
<th>-PV</th>
<th>P value (sig)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMP3 cut-off level ≥ 9.5</td>
<td>0.971 (0.918 to 0.994)</td>
<td>100.00</td>
<td>81.52</td>
<td>46.9</td>
<td>100.0</td>
<td>&lt;0.0001 (HS)</td>
</tr>
<tr>
<td>Ki-67 cut-off level ≥ 22.5</td>
<td>0.828 (0.743 to 0.894)</td>
<td>100.00</td>
<td>65.22</td>
<td>31.9</td>
<td>100.0</td>
<td>&lt;0.0001 (HS)</td>
</tr>
</tbody>
</table>

AUC: area under the curve; CI: confidence interval; +PV: positive predictive value; -PV: negative predictive value; sig: significance; HS: highly significant.

In the current study, IMP3 sensitivity and specificity in differentiating sinonasal SCC from noncancerous cases were 100% and 81.5%, respectively. This was unlike Maržič et al. and Chen et al. [6, 17], whose cases of laryngeal SCC did not show 100% sensitivity for IMP3 expression. Moreover, the present study showed heterogeneity in IMP3 expression among sinonasal SCC, such that negative areas were seen alternating with areas of low intensity in well-differentiated sinonasal SCC, focal strong cytoplasmic staining alternate with cytoplasmic staining of low intensity in moderately differentiated sinonasal SCC, and diffuse moderate to strong cytoplasmic staining in poorly differentiated sinonasal SCC. This was also recorded by Maržič et al. in laryngeal SCC, Ikenberg et al. in prostatic carcinoma, and Sakakibara et al. in esophageal carcinoma [6, 41, 42]. Whether such heterogeneous patterns reflect the recent assumption of the
Our current work revealed that IMP3 expression was significantly related to lymph node and tumor stages, but not to tumor grade. This was in agreement with Clauditz et al. [16], who found significant correlation between IMP3 expression in head and neck SCCs and both tumor and lymph node stages, but not tumor grade. Li et al. [15] revealed significant correlation between IMP3 expression in their cases of tongue SCC and lymph node stage but not with tumor stage nor tumor grade.

Guided by Zlobec et al. [44], ROC curves were plotted to detect cut-off scores of survival and progression for IMP3, and accordingly, Kaplan-Meier analysis was conducted which showed that IMP3 correlated with shorter OS, LRFS, and MFS at the estimated cut-off values (P < 0.0001). This was partly similar to Li et al. [15] whose cases of tongue SCC showed that IMP3 expression had significantly worse OS and lymph node metastasis. Clauditz et al. [16] also showed that IMP3 correlated with OS. However, unlike the current study, their study revealed no significance between IMP3 expression and recurrence-free survival.

A previous study has demonstrated some promising results that support the use of IMP3 as a potential vaccination therapy in patients with head and neck SCC, which showed an immune response that improved the OS of patients [45]. Another study revealed that local recurrence was the main cause of treatment failure in the sinonasal SCC on top of the IP group and suggested that a more aggressive but local treatment in the early stage may be helpful in improving prognosis in such patients [46].

The correlation between IMP3 expression to OS and higher incidence of local recurrence suggests targeting IMP3 might decrease the incidence of local recurrence, and thereby improve the prognosis of such cases [46].

The current study is the first to evaluate IMP3 IHC expression in three separate groups of samples from the sinonasal tract-normal sinonasal epithelium, IP, and SCC on top of IP. Among the points of strength of the current study was comparing the IMP3 IHC expression to an established biomarker of carcinogenesis, namely, Ki-67. It showed a potential diagnostic role for IMP3 in discriminating SCC on top of IP from noncancerous cases with sensitivity and specificity of 100% and 81.5%, respectively. This might suggest that in problematic cases, IMP3 IHC expression could serve as a low-cost ancillary aid. Nevertheless, more studies including dysplastic changes should be performed.

Moreover, the present study has demonstrated that IMP3 expression correlated with poor prognostic indicators and tumor progression in cases of SCC on top of IP. A potential therapeutic value in such cases could be achieved by targeting IMP3 in order to improve prognosis. However, only multi-institutional prognostic studies, to encompass a larger sample size, would be able to confirm the prognostic and therapeutic impact of IMP3 in this context.

Therefore, a limitation to this study is the small number of patients with IP-associated sinonasal SCC (15 cases). This might be attributed to the rarity of this diagnosis. Hence, we found it intriguing to explore all the data we had and to fully present it as a cornerstone for further studies to build upon.

<table>
<thead>
<tr>
<th>Table 4: Logistic regression to study independent factors associated with SCC.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Age</td>
</tr>
<tr>
<td>Gender (female)*</td>
</tr>
<tr>
<td>IMP3 expression</td>
</tr>
<tr>
<td>Ki-67 expression</td>
</tr>
</tbody>
</table>

*Reference male. CI: confidence interval.

<table>
<thead>
<tr>
<th>Table 5: Correlation between IMP3 and Ki-67 expression among the three studied groups.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal epithelium group</td>
</tr>
<tr>
<td>r</td>
</tr>
<tr>
<td>IMP3 expression</td>
</tr>
<tr>
<td>Sig</td>
</tr>
<tr>
<td>Inverted papilloma group</td>
</tr>
<tr>
<td>r</td>
</tr>
<tr>
<td>IMP3 expression</td>
</tr>
<tr>
<td>Sig</td>
</tr>
<tr>
<td>Sinonasal SCC</td>
</tr>
<tr>
<td>r</td>
</tr>
<tr>
<td>IMP3 expression</td>
</tr>
<tr>
<td>Sig</td>
</tr>
</tbody>
</table>

*Pearson correlation; **Spearmann’s rho.

<table>
<thead>
<tr>
<th>Table 6: Correlation between IMP3 and Ki-67 expression and clinicopathological parameters of SCC cases.</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMP3 expression</td>
</tr>
<tr>
<td>Lymph nodal stage</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Tumor histologic grade</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Tumor stage</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

*Spearman’s rho.

The correlation between IMP3 expression to OS and higher incidence of local recurrence suggests targeting IMP3 might decrease the incidence of local recurrence, and thereby improve the prognosis of such cases [46].

The current study is the first to evaluate IMP3 IHC expression in three separate groups of samples from the sinonasal tract-normal sinonasal epithelium, IP, and SCC on top of IP. Among the points of strength of the current study was comparing the IMP3 IHC expression to an established biomarker of carcinogenesis, namely, Ki-67. It showed a potential diagnostic role for IMP3 in discriminating SCC on top of IP from noncancerous cases with sensitivity and specificity of 100% and 81.5%, respectively. This might suggest that in problematic cases, IMP3 IHC expression could serve as a low-cost ancillary aid. Nevertheless, more studies including dysplastic changes should be performed.

Moreover, the present study has demonstrated that IMP3 expression correlated with poor prognostic indicators and tumor progression in cases of SCC on top of IP. A potential therapeutic value in such cases could be achieved by targeting IMP3 in order to improve prognosis. However, only multi-institutional prognostic studies, to encompass a larger sample size, would be able to confirm the prognostic and therapeutic impact of IMP3 in this context.

Therefore, a limitation to this study is the small number of patients with IP-associated sinonasal SCC (15 cases). This might be attributed to the rarity of this diagnosis. Hence, we found it intriguing to explore all the data we had and to fully present it as a cornerstone for further studies to build upon.
This study is one of a few IHC studies investigating IP-associated sinonasal SCC. In addition, it proposed novel insights about the attributes of IMP3 in cancer initiation and progression through evaluation of its IHC expression in normal, benign neoplastic, and frankly malignant sinonasal SCC. Such results not only help in offering a better understanding of sinonasal carcinogenesis but also provide a potential low-cost ancillary tool to resolve enigmatic differential diagnoses with high yield diagnostic accuracy in IP-associated sinonasal SCC detection. Furthermore, in the

<table>
<thead>
<tr>
<th>IMP3</th>
<th>AUC (CI)</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>+PV</th>
<th>-PV</th>
<th>P (sig)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall survival cut-off level ≥ 55</td>
<td>1.0 (1.0 to 1.0)</td>
<td>100.00</td>
<td>100.00</td>
<td>100.00</td>
<td>100.00</td>
<td>&lt;0.027 (S)</td>
</tr>
<tr>
<td>Local recurrence cut-off level ≥ 31</td>
<td>1.0 (1.0 to 1.0)</td>
<td>100.00</td>
<td>100.00</td>
<td>100.00</td>
<td>100.00</td>
<td>&lt;0.001 (HS)</td>
</tr>
<tr>
<td>Distant metastasis cut-off level ≥ 49</td>
<td>1.0 (1.0 to 1.0)</td>
<td>100.00</td>
<td>100.00</td>
<td>100.00</td>
<td>100.00</td>
<td>&lt;0.009 (HS)</td>
</tr>
</tbody>
</table>

**Table 7**: ROC analysis using IMP3 to predict mortality, local recurrence, and distant metastasis among SCC cases.

**Figure 5**: (a) Kaplan-Meier analysis showing correlation between IMP3 IHC expression and OS at a cut-off level >55; (b) Kaplan-Meier analysis showing correlation between IMP3 IHC expression and local recurrence-free at a cut-off level >31; (c) Kaplan-Meier analysis showing correlation between IMP3 IHC expression and distant metastasis at a cut-off level >49.

**5. Conclusion**

This study is one of a few IHC studies investigating IP-associated sinonasal SCC. In addition, it proposed novel insights about the attributes of IMP3 in cancer initiation and progression through evaluation of its IHC expression in normal, benign neoplastic, and frankly malignant sinonasal SCC. Such results not only help in offering a better understanding of sinonasal carcinogenesis but also provide a potential low-cost ancillary tool to resolve enigmatic differential diagnoses with high yield diagnostic accuracy in IP-associated sinonasal SCC detection. Furthermore, in the
malignant spectrum, IMP3 might also provide a promising prognostic marker and a potential therapeutic target.

Data Availability
All data generated or analyzed during this study are included in this published article.

Ethical Approval
The study was approved by the Research Ethical Committee (REC) at the Faculty of Medicine, Ain Shams University.

Consent
All patients who participated in this study signed a written informed consent before surgery.

Conflicts of Interest
The authors declare that they have no competing interests.

Authors’ Contributions
Sarah A. Hakim designed and coordinated the study, performed data collection and statistical analysis, reviewed the histological diagnosis, evaluated immunohistochemistry, and drafted the manuscript. Nermine M. Abd Raboh participated in the study design, reviewed the histological diagnosis, evaluated immunohistochemistry, carried out photographing, and coordinated and critically reviewed the manuscript. Lobna S. Shash participated in the study design, reviewed the histological diagnosis, evaluated immunohistochemistry, and coordinated and critically reviewed the manuscript. The authors read and approved the final manuscript.

References


